AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
Published on July 14, 2026
AstraZeneca to license lung cancer drug from China’s Dizal Pharmaceutical
